Lucid Genomics and the Genetic Alliance announced a collaboration to expand access to Lucid’s AI-powered sequencing analysis platform for underserved rare disease patients. Under the agreement, Lucid will share its software for use by nine laboratories participating in Genetic Alliance’s rare disease genomics program, which provides free clinical genomic testing through a network of 26 clinical sites. The partnership targets a key operational bottleneck: the cost and investment required for sequencing interpretation tools. Lucid described its in-kind software contribution as a way to redirect resources toward genomic testing itself, including work supporting both short- and long-read sequencing data. For the genomics ecosystem, the deal illustrates how model-driven analytics are being embedded into clinical workflows beyond major academic centers, with access expansion framed as an infrastructure-and-software problem.